MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Løkkegaard S, Elias D, Alves CL, Bennetzen MV, Lænkholm AV, Bak M, Gjerstorff MF, Johansen LE, Vever H, Bjerre C, Kirkegaard T, Nordenskjöld B, Fornander T, Stål O, Lindström LS, Esserman LJ, Lykkesfeldt AE, Andersen JS, Leth-Larsen R, Ditzel HJ.
Løkkegaard S, et al. Among authors: fornander t.
NPJ Breast Cancer. 2021 Jan 4;7(1):2. doi: 10.1038/s41523-020-00210-8.
NPJ Breast Cancer. 2021.
PMID: 33398005
Free PMC article.